Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
Status:
Completed
Trial end date:
2018-01-18
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate the longterm impact on cardiovascular morbidity,
mortality and renal function of treatment with linagliptin in a selected population of
patients with Type 2 diabetes mellitus (T2DM) and to compare outcomes against placebo, on a
background of standard of care.